Leishmania amazonensis is one of the Leishmania species that cause leishmaniasis in Brazil, an endemic disease present in several countries. The disease can cause death and is considered by the World Health Organization a neglected tropical disease. Currently available treatments are expensive, long-lasting, and offer cardiac, hepatic and renal risks to those infected. In some cases, treatment is not effective in controlling infection, and selection of drug-resistant parasites is a major concern. Thus, this project aims to identify possible drugs approved for use in humans that may contribute to the control of L. amazonensis replication in macrophages. The development of this work will help in the future development of effective therapeutic strategies for the treatment of leishmaniasis caused by several species of Leishmania.
News published in Agência FAPESP Newsletter about the scholarship: